Showing results (21-30 of 51) with videos related to
Sort By:
Pageof 6
Experimental Gerontology|March 31, 2004
Characterization of naïve, memory and effector CD8+ T cells: effect of ageSudhir Gupta, Ruifen Bi, Kevin Su, et al.Molecular Cancer Therapeutics|August 27, 2003
Arsenic trioxide induces apoptosis in peripheral blood T lymphocyte subsets by inducing oxidative stress: a role of Bcl-2Sudhir Gupta, Leman Yel, Daniel Kim, et al.International Immunopharmacology|April 6, 2019
Population pharmacokinetic modeling and simulation of immunoglobulin exposure with varying dosing intervals of subcutaneous immunoglobulin 20% (Ig20Gly) in patients with primary immunodeficiency diseasesTodd Dumas, N Seth Berry, Martin Wolfsegger, et al.BMC Immunology|May 6, 2020
Patient experience with subcutaneous immunoglobulin 20%, Ig20Gly, for primary immunodeficiency diseases: a prespecified post hoc analysis of combined data from 2 pivotal trialsLisa M Meckley, Yanyu Wu, Diane Ito, et al.Journal of Clinical Immunology|May 28, 2004
Antibody response to a seven-valent pneumococcal conjugated vaccine in patients with ataxia-telangiectasiaOzden Sanal, Fugen Ersoy, Ilhan Tezcan, et al.Journal of Clinical Immunology|December 22, 2023
A Phase 1 Open-Label Study to Assess the Tolerability, Safety, and Immunogenicity of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 20% in Healthy AdultsAndras Nagy, Kimberly Duff, Alexander Bauer, et al.The Pediatric Infectious Disease Journal|April 7, 2007
A case of interleukin-12 receptor beta-1 deficiency with recurrent leishmaniasisOzden Sanal, Gulten Turkkani, Fatma Gumruk, et al.Immunotherapy|December 21, 2021
Infection rates and tolerability of three different immunoglobulin administration modalities in patients with primary immunodeficiency diseasesRichard L Wasserman, Sudhir Gupta, Mark Stein, et al.Blood|September 11, 2004
Molecular analysis of a large cohort of patients with the hyper immunoglobulin M (IgM) syndromeWen-I Lee, Troy R Torgerson, Michael J Schumacher, et al.Journal of Clinical Immunology|June 19, 2024
Tolerability and Safety of Large-Volume Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% Administered with or without Dose Ramp-Up: A Phase 1 Study in Healthy ParticipantsZhaoyang Li, Andras Nagy, Dirk Lindner, et al.Pageof 6